Revenue of $3.9M during the quarter ended December 31, 2025 reflects sales related to the launch of Lymphir. Cash and cash equivalents totaled $7.3M as of December 31, 2025 .
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
- Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
- CTOR Earnings this Week: How Will it Perform?
- Citius files to sell shares of common stock underlying warrants for holders
- Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption